Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission

被引:0
|
作者
Qiang Zeng
Bing Xiang
Zhigang Liu
机构
[1] West China Hospital,Department of Hematology and Institute of Hematology
[2] Sichuan University,undefined
来源
Annals of Hematology | 2022年 / 101卷
关键词
Auto-HSCT; AML; IL-2;
D O I
暂无
中图分类号
学科分类号
摘要
High-dose chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) is generally the optimal option for patients with acute myeloid leukemia (AML). However, for favorable- and intermediate-risk patients, the regimen remains less understood due to graft versus host disease (GVHD) and increased non-relapsed mortality (NRM) caused by allo-HSCT. Additionally, the benefit of maintenance therapy has not yet been conclusively proven. Here, we conducted a retrospective study on the long-term outcome of AML patients with favorable or intermediate risk who underwent autologous hematopoietic stem cell transplantation (auto-HSCT) followed by interleukin-2 (IL-2) subcutaneous injection as maintenance therapy. A total of 49 patients from 2007 to 2019 were included in our study. They all received a daunorubicin + cytarabine regimen as induction chemotherapy followed by four to six cycles of consolidation therapy with medium- or high-dose cytarabine. Once patients achieved complete remission (CR1), they started receiving auto-HSCT followed by IL-2 injections. The results showed that no patients stopped receiving IL-2 injections on account of adverse side effects, and the 5-year overall survival (OS) and leukemia-free survival (LFS) rates were 85.6 ± 5.0% and 78.5 ± 6.1%, respectively. The multivariate analysis also suggested that age, gender, initial white blood cell (WBC) count, AML subtype, cytogenetic risk, and conditioning regimen did not affect the prognosis. In conclusion, auto-HSCT followed by IL-2 injection is an effective treatment that can improve the prognosis of AML for patients with favorable or intermediate risk.
引用
收藏
页码:1711 / 1718
页数:7
相关论文
共 50 条
  • [41] OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN THIRD REMISSION
    Beitinjaneh, A.
    Jakob, J.
    Saliba, R.
    Chen, J.
    Rondon, G.
    Giralt, S.
    Cortes, J. E.
    Champlin, R.
    De Lima, M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S328 - S328
  • [42] A cytogenetic model predicts relapse risk and survival in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation in morphologic complete remission
    Rashidi, Armin
    Cashen, Amanda F.
    LEUKEMIA RESEARCH, 2015, 39 (01) : 77 - 81
  • [43] A Cytogenetic Model Predicts Relapse Risk and Survival in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation in Morphologic Complete Remission
    Rashidi, Armin
    Cashen, Amanda F.
    BLOOD, 2014, 124 (21)
  • [44] Peripheral Blood Stem Cell Collection after Intermediate-Dose Cytarabine in Adult Patients with Acute Myeloblastic Leukemia Undergoing Autologous Blood Stem Cell Transplantation in First Complete Remission
    J. de la Rubia
    G. Martín
    J. Martínez
    I. Lorenzo
    G. Sanz
    I. Jarque
    F. Moscardó
    C. Jiménez
    P. Lorente
    A. Camps
    M. A. Sanz
    International Journal of Hematology, 2004, 80 : 168 - 173
  • [45] Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia
    Bondarenko, Sergey
    Moiseev, Ivan
    Morozova, Elena
    Vlasova, Yulia
    Smirnova, Anna
    Tsvetkov, Nikolai
    Beinarovich, Anastasiya
    Gindina, Tatiana
    Babenko, Elena
    Barkhatov, Ildar
    Alyanskiy, Alexander
    Zubarovskaya, Ludmila
    Kulagin, Alexander
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 191 - 192
  • [46] Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remission
    de la Rubia, J
    Martín, G
    Martínez, J
    Lorenzo, I
    Sanz, G
    Jarque, I
    Moscardó, F
    Jiménez, C
    Lorente, P
    Camps, A
    Sanz, MA
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 80 (02) : 168 - 173
  • [47] Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate risk karyotype in first complete remission
    Hemmati, P.
    Terwey, T.
    Na, I. -K.
    le Coutre, P.
    Jehn, C.
    Vuong, L.
    Doerken, B.
    Arnold, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 131 - 132
  • [48] Lack of benefits of additional chemotherapy after complete remission prior to hematopoietic stem cell transplantation in patients with acute myeloid leukemia: Seattle experience
    Aljohani, N.
    Othus, M.
    Estey, E.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S59 - S59
  • [49] A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission
    Cortes, JE
    Kantarjian, HM
    O'Brien, S
    Giles, F
    Keating, MJ
    Freireich, EJ
    Estey, EH
    CANCER, 1999, 85 (07) : 1506 - 1513
  • [50] Is autologous hematopoietic stem cell transplantation for acute myeloid leukemia still an option?
    Simancikova, I.
    Bojtarova, E.
    Hrubisko, M.
    Farkas, F.
    Horvathova, D.
    Sopko, L.
    Batorova, A.
    Mistrik, M.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S496 - S496